Holen Sie sich die Stockscreener-App
10.15
3.57%
0.3535
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Brokers Offer Predictions for STOK FY2025 Earnings - MarketBeat
Possible Signal As Stoke Therapeutics Insiders Sell US$523k In Stock - Simply Wall St
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN
When the Price of (STOK) Talks, People Listen - Stock Traders Daily
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 9.7%Time to Buy? - MarketBeat
Barclays PLC Raises Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Is Stoke Therapeutics Inc (NASDAQ: STOK) Still Trending? - Stocks Register
Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Head-To-Head Contrast: Inhibitor Therapeutics (OTCMKTS:INTI) and Stoke Therapeutics (NASDAQ:STOK) - Defense World
Stoke Therapeutics Inc (STOK): Worth A Small Bite At $8.92 - Stocks Register
Wedbush Equities Analysts Raise Earnings Estimates for STOK - MarketBeat
What is Wedbush’s Estimate for STOK FY2029 Earnings? - Defense World
Research Analysts Offer Predictions for STOK FY2029 Earnings - MarketBeat
Learn to Evaluate (STOK) using the Charts - Stock Traders Daily
Stoke Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Analyst maintains OW rating on Stoke Therapeutics as P3 EMPEROR study design finalized - Investing.com Canada
Needham & Company LLC Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC Wainwright - MarketBeat
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts - Benzinga
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownTime to Sell? - MarketBeat
Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study - TipRanks
STOKStoke Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Stoke Therapeutics aligns with regulators on Dravet study - Investing.com
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome - Business Wire
Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $21.29 - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Stoke Therapeutics Advances First Disease-Modifying Dravet Syndrome Treatment to Phase 3 - StockTitan
Franklin Resources Inc. Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Geode Capital Management LLC Boosts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Geode Capital Management LLC Buys 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Barclays PLC Purchases 47,239 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Holdings Lifted by Barclays PLC - MarketBeat
When (STOK) Moves Investors should Listen - Stock Traders Daily
Skorpios Trust Reduces Stake in Stoke Therapeutics Inc - GuruFocus.com
Stoke therapeutics sees $23 million stock sale by Skorpios Trust - Investing.com Canada
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Trading Down 2.9%Should You Sell? - MarketBeat
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow - Yahoo Finance
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by State Street Corp - Defense World
State Street Corp Grows Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down – What’s Next? - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Chardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy Recommendation - MSN
Stoke Therapeutics (NASDAQ:STOK) Now Covered by Chardan Capital - MarketBeat
Jane Street Group LLC Acquires 255,028 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
(STOK) Proactive Strategies - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5%What's Next? - MarketBeat
0.98%
7.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):